Evidence standard: Claims are graded by study type. Human Phase 2 RCT data is distinguished from animal and mechanistic findings throughout.
Regulatory note: Retatrutide is not FDA approved. It remains in Phase 3 trials as of this writing.
Trust Signals
- Primary clinical source: Jastreboff et al., "Triple-Hormone-Receptor Agonist Retatrutide for Obesity," New England Journal of Medicine, 2023.
- Pharmacokinetic data sourced from Eli Lilly Phase 1 disclosures and clinical trial registry entries (NCT05394519).
- No affiliate incentive influences clinical claims on this page.
- Speculative or mechanistic-only claims are labeled as such in the evidence ledger.
Key Takeaways
- Retatrutide is injected subcutaneously once weekly. The Phase 2 trial used a starting dose of 2 mg per week, titrated to maintenance doses of 4 mg, 8 mg, or 12 mg.
- At 24 weeks, the 12 mg group achieved a mean body weight reduction of approximately 17.5% in the Jastreboff et al. NEJM 2023 trial (n=338 for the dose-finding arms combined).
- The estimated half-life is approximately 6 days, making once-weekly dosing pharmacokinetically appropriate.
- Nausea, vomiting, and diarrhea were the most common adverse events and were concentrated during dose-escalation weeks.
- Retatrutide is not approved. Any vial purchased outside a registered clinical trial is a research compound with no guarantee of identity, purity, or sterility.
Direct Answer: How to Take Reta Peptide
Reta peptide (retatrutide) is taken as a once-weekly subcutaneous injection, typically into the abdomen, thigh, or upper arm. In the pivotal Phase 2 trial, dosing started at 2 mg per week and was titrated upward over several weeks to a maintenance dose between 4 mg and 12 mg. It is not an oral or intranasal compound.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of Contents
- What is retatrutide and how does it work?
- What does the human evidence actually show?
- What dose is used and how is it titrated?
- How do you perform the injection correctly?
- How do you reconstitute and measure a dose?
- How should reta peptide be stored?
- What most pages get wrong about retatrutide
- Honest head-to-head: retatrutide vs. semaglutide vs. tirzepatide
- How to read a retatrutide COA and vial label
- What are the side effects and how are they managed?
- FAQ
- Sources
What Is Retatrutide and How Does It Work?
Retatrutide is a synthetic 39-amino-acid peptide developed by Eli Lilly that simultaneously activates three receptors: glucagon-like peptide-1 receptor (GLP-1R), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon receptor (GCGR). This distinguishes it from semaglutide (GLP-1R only) and tirzepatide (GLP-1R and GIPR).
The GLP-1R component slows gastric emptying and reduces appetite. The GIPR component appears to complement GLP-1 signaling and may modulate reward-related eating behavior. The GCGR component increases hepatic glucose output and, more relevant to weight loss, raises basal energy expenditure by stimulating thermogenesis. Glucagon receptor agonism in isolation would raise blood glucose, but co-activation of GLP-1R counteracts that effect, producing a net metabolic state of increased energy expenditure without hyperglycemia. This is the proposed mechanistic rationale for retatrutide's larger weight loss signal compared to dual agonists. It is a plausible mechanism supported by rodent data and consistent with Phase 2 human outcomes, but the relative contribution of each receptor pathway in humans has not been isolated experimentally.
What Does the Human Evidence Actually Show?
| Claim | Best Evidence Type | Effect Direction | Confidence |
|---|---|---|---|
| Once-weekly subcutaneous dosing is effective | Human Phase 2 RCT (Jastreboff et al., NEJM 2023) | Positive | Moderate (Phase 2, not Phase 3) |
| 12 mg dose produces roughly 17.5% body weight loss at 24 weeks | Human Phase 2 RCT | Positive | Moderate |
| Glucagon receptor activity raises energy expenditure in humans | Mechanistic inference from receptor pharmacology and rodent studies | Likely positive | Low (not directly measured in Phase 2) |
| GI adverse events (nausea, vomiting) are dose-dependent | Human Phase 2 RCT | Positive (harm direction) | Moderate |
| Cardiovascular outcome benefit | No human outcomes trial published as of May 2026 | Unknown | Very Low |
| Long-term weight maintenance after stopping | No published data | Unknown | Very Low |
| Superiority to tirzepatide in a head-to-head RCT | No head-to-head RCT published | Unknown | Very Low |
What Dose Is Used and How Is It Titrated?
The Jastreboff 2023 Phase 2 trial used the following escalation schema for reference:
| Weeks | Dose (once weekly) | Purpose |
|---|---|---|
| 1 to 4 | 2 mg | Tolerability establishment |
| 5 to 8 | 4 mg (or held if not tolerated) | Escalation |
| 9 to 12 | 8 mg (high-dose arms) | Escalation |
| 13 onward | 4 mg, 8 mg, or 12 mg (by arm) | Maintenance |
These are trial protocol doses, not prescribing guidelines. Phase 3 titration schedules may differ. Starting above 2 mg without a slow titration is associated with higher rates of nausea and discontinuation based on the trial's adverse event data.
How Do You Perform the Injection Correctly?
Retatrutide is a subcutaneous peptide. Intramuscular injection is not the target route and would alter absorption kinetics.
Needle selection: 28 to 31 gauge, 4 to 8 mm length insulin syringe. A 4 mm needle reaches subcutaneous depth in most adults without risk of intramuscular injection. In individuals with very low body fat, a 4 mm needle is preferred for the same reason.
Sites: Rotate among abdomen (2 inches from navel minimum), outer thigh, and posterior upper arm. Rotating sites reduces lipodystrophy and injection-site nodule formation.
Technique: Pinch skin gently if using a longer needle. Insert at 45 to 90 degrees depending on needle length and adipose thickness. Inject slowly, withdraw, apply light pressure without rubbing. Do not inject into areas of active bruising, irritation, or lipodystrophy.
Timing: Same day each week. If a dose is missed by less than 2 days, inject as soon as remembered and resume the weekly schedule. If more than 2 days have passed, skip and resume the next scheduled dose. This guidance mirrors the approach used for other once-weekly GLP-1 class agents and is not retatrutide-specific from a clinical trial standpoint.
How Do You Reconstitute and Measure a Dose?
Research-grade retatrutide is commonly sold as lyophilized powder in vials of 2 mg, 5 mg, or 10 mg. The following math applies once you confirm the actual vial contents from the accompanying certificate of analysis.
Example: 10 mg vial, target concentration 5 mg per mL
- Add 2.0 mL bacteriostatic water (BAC water) slowly down the side of the vial. Do not inject directly onto the powder cake.
- Swirl gently until dissolved. Do not shake (agitation can cause aggregation).
- Resulting concentration: 5 mg per mL, or 5,000 mcg per mL.
- A 2 mg dose at this concentration requires 0.4 mL (40 units on a 100-unit insulin syringe).
- A 4 mg dose requires 0.8 mL (80 units).
Always verify: Draw the solution to a clean light source. It should be clear and colorless to very slightly yellow. Cloudy, particulate, or strongly discolored solution should be discarded.
How Should Reta Peptide Be Stored?
Lyophilized peptide powder is the most stable form. Store at 2 to 8 degrees Celsius (standard refrigerator temperature) and shield from light. The peptide backbone is vulnerable to hydrolysis and oxidation. Heat accelerates both pathways. Freeze-thaw cycling can cause aggregation and loss of activity.
After reconstitution with bacteriostatic water (which contains benzyl alcohol as a preservative), the general guideline used across injectable peptide classes is use within 28 days when kept refrigerated. Without benzyl alcohol (sterile water only), use within a shorter window, typically 3 to 5 days, because microbial growth is not suppressed.
Do not leave reconstituted solution at room temperature for extended periods. The specific degradation kinetics for retatrutide have not been published in open literature, but the general principle applies: peptide amide bonds hydrolyze faster at higher temperatures and the rate roughly doubles with every 10 degree Celsius increase (Arrhenius approximation), a well-established physical chemistry relationship.
What Most Pages Get Wrong About Retatrutide
Most content on how to take reta peptide treats Phase 2 trial doses as settled prescribing guidance and glosses over four critical realities:
1. Purity of research-grade material is not guaranteed. Retatrutide is a 39-amino-acid peptide. Solid-phase peptide synthesis at this length produces truncated sequences, deletion variants, and racemization products if quality control is inadequate. A certificate of analysis from a credible third-party HPLC lab should show purity above 98% with identity confirmed by mass spectrometry. A COA showing only HPLC purity without mass spec confirmation is insufficient to confirm you have retatrutide and not an analog or truncated fragment.
2. Sterility is a separate question from purity. Research-grade peptides sold as lyophilized powder are not held to pharmaceutical sterile manufacturing standards. The buyer performs reconstitution in a non-sterile environment. Endotoxin contamination (pyrogens from bacterial membrane fragments) can cause fever and systemic inflammation at concentrations too low to see visually. This risk is real and under-discussed in community protocols.
3. The 17.5% weight loss figure is a 24-week mean, not a guarantee. The Jastreboff trial excluded people with prior bariatric surgery, certain comorbidities, and recent use of other weight-affecting medications. The placebo arm also lost weight (roughly 1.6% at 24 weeks), meaning the drug effect net of placebo was approximately 16 percentage points, not the raw 17.5%. Individual response varies substantially.
4. Glucagon agonism is not consequence-free. GCGR activation increases hepatic glucose production and can raise heart rate. In the Phase 2 trial, mean heart rate increased in the retatrutide groups. People with conditions sensitive to heart rate elevation should factor this in.
Honest Head-to-Head: Retatrutide vs. Semaglutide vs. Tirzepatide
| Feature | Retatrutide | Tirzepatide (Zepbound) | Semaglutide (Wegovy) |
|---|---|---|---|
| Receptor targets | GLP-1R, GIPR, GCGR (triple) | GLP-1R, GIPR (dual) | GLP-1R (single) |
| Best observed weight loss (human trial) | Approx. 17.5% at 24 weeks (Phase 2) | Approx. 20.9% at 72 weeks (Phase 3, SURMOUNT-1) | Approx. 14.9% at 68 weeks (STEP 1) |
| FDA approval status | Not approved (Phase 3) | Approved (obesity, 2023) | Approved (obesity, 2021) |
| Cardiovascular outcomes data | None published | SELECT trial positive for semaglutide; tirzepatide SURPASS-CVOT ongoing | SELECT trial: 20% CV event reduction (NEJM 2023) |
| GI side effect burden | Moderate to high (dose-dependent) | Moderate | Moderate |
| Heart rate increase | Yes (Phase 2 data) | Minimal | Small increase reported |
| Access | Research compound only | Prescription, commercial | Prescription, commercial |
| Where retatrutide loses | No approval, no outcomes data, no quality guarantee outside trials | Longer follow-up data available | Best cardiovascular outcomes evidence |
Retatrutide's Phase 2 weight loss numbers are impressive but were measured at 24 weeks. SURMOUNT-1 tirzepatide data at 72 weeks shows higher absolute weight loss. Comparing 24-week and 72-week data is not apples-to-apples. No superiority can be claimed from current published evidence.
How to Read a Retatrutide COA and Vial Label
When evaluating any research-grade retatrutide, request and verify the following before use:
| Document Element | What to Look For | Red Flag |
|---|---|---|
| HPLC purity | Greater than 98% area under curve | Below 95%, or no chromatogram provided |
| Mass spectrometry | Molecular weight matching retatrutide (published MW approximately 4530 Da based on sequence); exact figure should match vendor claim | No MS data at all |
| Third-party lab | Named, independent analytical lab, not the vendor's own facility | In-house testing only |
| Endotoxin testing | LAL (limulus amebocyte lysate) test result below relevant threshold | Absent entirely |
| Lot number | Matches the vial label exactly | Mismatch or generic LOT entry |
| Vial label | Peptide name, mg amount, lot number, expiry, storage instructions | Missing mg amount or no expiry |
What Are the Side Effects and How Are They Managed?
Based on the Jastreboff et al. Phase 2 trial, the most common adverse events by frequency were nausea, vomiting, diarrhea, and decreased appetite. These were predominantly mild to moderate and most common during dose-escalation periods. Discontinuation due to adverse events was higher in the 12 mg group than in placebo, though the trial paper does not report a single pooled discontinuation rate across all arms that I can reproduce with decimal precision here.
Management approach used in trials and analogous GLP-1 class agents:
- Slow titration is the primary mitigation. Rushing escalation is the main driver of GI events.
- Eating smaller meals, avoiding high-fat meals, and staying hydrated reduces nausea severity.
- Anti-emetics (ondansetron, promethazine) are sometimes used for severe nausea, though this is not protocol-specified for retatrutide research.
- Dose reduction to the prior tolerated level is preferable to discontinuation when GI events occur.
Heart rate elevation was noted in the Phase 2 trial. People with baseline tachycardia, arrhythmia history, or significant cardiovascular disease should not self-administer this compound outside medical supervision.
FAQ
How do you take reta peptide?
Retatrutide is administered as a subcutaneous injection once weekly. In the Phase 2 trial by Jastreboff et al. (NEJM 2023), participants started at 2 mg per week and doses were titrated upward over several weeks based on tolerability, reaching maintenance doses between 4 mg and 12 mg per week.
What dose of retatrutide is used?
The Phase 2 trial tested maintenance doses of 4 mg, 8 mg, and 12 mg once weekly. The 12 mg group achieved the highest mean weight loss, approximately 17.5% of body weight at 24 weeks. Phase 3 dosing may differ from these research figures.
Where do you inject reta peptide?
Subcutaneous injection sites include the abdomen (at least 2 inches from the navel), outer thigh, or upper arm. Sites should be rotated with each weekly injection to reduce lipodystrophy and injection-site reactions.
How do you reconstitute retatrutide powder?
Add bacteriostatic water slowly along the vial wall, do not shake. A common research vial of 10 mg dissolved in 2 mL bacteriostatic water yields 5 mg per mL. Always verify vial concentration before drawing any dose.
How often do you inject retatrutide?
Once weekly, on the same day each week. The half-life of retatrutide is approximately 6 days based on Phase 1 pharmacokinetic data, which supports a once-weekly dosing interval to maintain steady-state plasma levels.
What needle size should be used for reta peptide injection?
A 28 to 31 gauge, 4 to 8 mm insulin syringe is appropriate for subcutaneous injection in most adults. Shorter needles (4 mm) are adequate for subcutaneous depth; longer needles increase risk of intramuscular injection in leaner individuals.
How should retatrutide be stored?
Lyophilized (freeze-dried) powder should be stored at 2 to 8 degrees Celsius protected from light. After reconstitution with bacteriostatic water, refrigerate and use within 28 days. Peptide bonds degrade faster at room temperature and above.
What are the most common side effects of retatrutide?
In the Jastreboff et al. Phase 2 trial, nausea, vomiting, diarrhea, and decreased appetite were the most frequent adverse events and were most common during dose escalation. Most were rated mild to moderate. Discontinuation due to adverse events was higher in the 12 mg group than placebo.
Is retatrutide FDA approved?
No. As of May 2026, retatrutide is not FDA approved. It is in Phase 3 clinical trials. Any retatrutide available outside a clinical trial is a research compound with no regulatory approval for human therapeutic use.
How is retatrutide different from semaglutide or tirzepatide?
Retatrutide is a triple agonist acting on GLP-1, GIP, and glucagon receptors simultaneously. Semaglutide is a GLP-1 mono-agonist. Tirzepatide is a GLP-1 and GIP dual agonist. The added glucagon receptor activity in retatrutide may drive greater energy expenditure, which is one proposed mechanism for its higher observed weight loss in early trials.
Can you mix retatrutide with other peptides in the same syringe?
No published stability or compatibility data supports mixing retatrutide with other peptides in a single syringe. Until such data exist, mixing is not recommended because pH differences and competing degradation pathways can accelerate breakdown of one or both compounds.
What does a degraded retatrutide vial look like?
Visible particulates, cloudiness in a solution that was clear at reconstitution, discoloration, or an unusual odor are all signs of degradation or contamination. Discard any vial showing these signs. Lyophilized powder that has turned yellow or formed a cake resistant to dissolution may also be compromised.
Sources
- Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity. New England Journal of Medicine. 2023;389(6):514-526. PMID: 37366315.
- Lilly Investor Update: Retatrutide Phase 3 TRIUMPH program initiation, 2023. Available via Eli Lilly investor relations.
- ClinicalTrials.gov Identifier NCT05394519: A Study of Retatrutide (LY3437943) in Participants with Obesity or Overweight.
- Finan B, Yang B, Ottaway N, et al. A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nature Medicine. 2015;21(1):27-36. (Background on triple agonist class.)
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine. 2023;389(24):2221-2232. (SELECT trial, semaglutide CV outcomes.)
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022;387(3):205-216. (SURMOUNT-1.)
- United States Pharmacopeia (USP) General Chapter 1, Injections and Implanted Drug Products. (Standards for subcutaneous injectable preparations.)